BioSpace News Archive

Hyperfine, Inc., creator of the Swoop® Point-of-Care MRI System™ for imaging of the brain, today announced the acceptance of twelve abstracts related to the Swoop® system to be presented at the prestigious International Society for Magnetic Resonance in Medicine (ISMRM) and International Society of MR Radiologist and Technologists (ISMRT) annual meeting.

The Kenya Medical Research Institute, NEC Corporation and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in Kenya.

J INTS BIO announced that the preclinical results of “JIN-A04,” a novel oral tyrosine kinase inhibitor targeting HER2 Exon20 insertion mutation in NSCLC, will be presented at the upcoming 2023 American Cancer Research Association meeting in Orlando, U.S. from April 14 to 19.

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting results of its collaboration with the Microbiology Laboratory of the Queen Elizabeth Hospital of Health PEI (“ Health PEI ”), in support of provincial adoption of molecular diagnostic (“ MDx ”) screening for Human Papillomavirus (“ HPV ”) infections.

LAVA Therapeutics N.V. today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023.

Silence Therapeutics plc today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff, SVP, Technical Operations.

Sensei Biotherapeutics, Inc. today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody.

Clearside Biomedical, Inc. today announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023.

Revolo Biotherapeutics today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting, which is being held February 24-27 in San Antonio, Texas.

Atreca, Inc. (Atreca) (NASDAQ: BCEL) and Xencor, Inc. (NASDAQ: XNCR) today announced, as part of their existing strategic collaboration, they have mutually selected the first program combining an Atreca-discovered antibody with Xencor’s XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).